FUJIFILM Holdings Corporation in 2 stories
The narratives 4901.T currently appears in, with its side and exposure in each.
Bull side
2 stories- Drug Manufacturing De-Risks From China
4901.T in “Drug Manufacturing De-Risks From China”
FadingExposure: not rated yetWestern drugmakers are paying for non-Chinese capacity before procurement restrictions become binding.
Fujifilm Diosynth's expanding US and European capacity is well placed to win diversified biologics production contracts.
- The Patent Cliff Sparks a Biotech Land Grab
4901.T in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Its expanding biologics CDMO network is positioned to capture outsourced development and manufacturing work generated by pipeline acquisitions.
Bear side
0 storiesNo bear-side stories for 4901.T yet.